Clinical trials: Neoplasms, Pharyngeal
Hypopharyngeal Carcinoma
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.
- Trial name
- NCT05494190
- Testing
- Docetaxel, Cisplatin, Capecitabine
- Where
- 3 sites in China
- Volunteers
- 111 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer
The purpose of this study is to compare the efficacy and toxicity of docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent radiotherapy with cetuximab or weekly cisplatin in locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT01614938
- Testing
- Cetuximab, Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
The trial aimed to compare cadonilimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in high-risk locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- GEMSTONE (NCT05587374)
- Testing
- Cadonilimab, Gemcitabine, Cisplatin
- Where
- 18 sites in China
- Volunteers
- 490 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to examine the efficacy of maintenance chemotherapy for the treatment of metastatic nasopharyngeal carcinoma. Participants will be randomized to 3 arms.
- Trial name
- NCT02944708
- Testing
- Conventional chemotherapy, Maintenance chemotherapy 1, Maintenance chemotherapy 2
- Where
- 14 sites in China, Singapore and 1 more
- Volunteers
- 384 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Nasopharyngeal Carcinoma
Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC
This is a randomized clinical trial comparing neoadjuvant and adjuvant PD-1 inhibitor Toripalimab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy…
- Trial name
- NCT04557020
- Testing
- PD-1 antibody, Gemcitabine, Cisplatin
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Oropharyngeal Cancer, Human Papillomavirus
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time
This research is being done to understand more about a sexually transmitted virus called Human papillomavirus (HPV) in people with oropharyngeal cancer and their partners.
- Trial name
- HOTSPOT (NCT01342978)
- Where
- 4 sites in United States
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Nasopharyngeal Neoplasms
Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
The present study will be a randomized, control, multicenter phase III study of recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) treated with Gemcitabine (Gemzar, Lilly) and cisplatin regimen (GP) or 5-Fluorouracil…
- Trial name
- NCT01528618
- Testing
- gemcitabine and cisplatin, 5-Fluorouracil and cisplatin
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Sun Yat-sen University
Multi-omics Technique, Nasopharyngeal Carcinoma
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
The observational clinical study will recruit 50 recurrent and/or metastatic nasopharyngeal carcinoma (r/mNPC) patients, to investigate the prediction values of multi-omics technique for the efficacy of chemoradiotherapy combined…
- Conditions
- Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma, Efficacy of Chemoradiotherapy and Immunotherapy
- Trial name
- NCT06197776
- Testing
- cisplatin-based chemoradiotherapy combined with immunotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Recurrent Nasopharyngeal Carcinoma
Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
The purpose of this study is to compare chemotherapy plus immunotherapy with immunochemotherapy combined subsequent locoregional radiotherapy in recurrent nasopharyngeal carcinoma (NPC), in order to confirm the value of…
- Trial name
- NCT07088484
- Testing
- ICI-chemotherapy and LIMT
- Volunteers
- 50 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other…
- Trial name
- NCT00431210
- Testing
- Epstein-Barr virus-specific adoptive T-cells immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Dana-Farber Cancer Institute
Hypopharyngeal Carcinoma, Laryngeal Carcinoma
Interest of MRI in Preoperative Staging for the Laryngeal and Hypopharyngeal Cancer
To determine if MRI can detect preoperative invasion of cartilage by laryngeal and hypopharyngeal carcinoma, and to compare it to CT imaging and histopathology in excised larynges and/or hypopharynges.
- Trial name
- Larynx MRI (NCT03132727)
- Testing
- Pharyngo laryngeal MRI
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Hospices Civils de Lyon
Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
This study aims to evaluate the efficacy and safety of LDRT combined with toripalimab and GP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma through a prospective, open-label, single-arm Phase II…
- Trial name
- LIGHT (NCT07325539)
- Testing
- Gemcitabine(GEM), Cisplatin, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Mucositis Oral
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy.
- Conditions
- Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
- Trial name
- NCT00293462
- Testing
- sargramostim, oral salt and soda mouthwash
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Marilyn Dodd
Nasopharyngeal Carcinoma
Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma
Endostar Continuous Intravenous Infusion Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT03932266
- Testing
- Endostar, Cisplatin, Docetaxel
- Volunteers
- 73 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Cancer of Head and Neck, Mucositis Oral
Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial
Patients with head and neck cancer generally receive a standard of care of 7 weeks of daily radiation therapy given alongside an aggressive chemotherapy drug called cisplatin.
- Conditions
- Cancer of Head and Neck, Mucositis Oral, Pharyngeal Mucositis
- Trial name
- NCT05331131
- Testing
- Ketamine Topical
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwell Health
Nasopharyngeal Cancer
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01074021
- Testing
- Nimotuzumab
- Where
- 24 sites in China
- Volunteers
- 480 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Malignant Dysphagia, Esophageal Cancer
Optimal Management of Malignant Dysphagia
According to the Canadian Cancer Society there are approximately 1700 new cases of esophageal cancer per year in Canada. As most of these patients are diagnosed in advanced stages of the disease, 1800 deaths are estimated from…
- Trial name
- NCT01366833
- Testing
- Brachytherapy, Stent insertion
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Nasopharyngeal Carcinoma
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
This study aims to explore a new, more effective and tolerable treatment regimen for patients with advanced recurrent/metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05854849
- Testing
- Camrelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Sun Yat-sen University
Radiation-associated Dysphagia, Head &Amp; Neck Cancer
Novel Treatment of Radiation Associated Dysphagia With Statins
The aim of this trial is to examine the feasibility, acceptability, and potential efficacy of a 12-month course of pravastatin as an antifibrotic agent for managing dysphagia (swallowing problems) in patients previously treated…
- Trial name
- TRADstat (NCT07217938)
- Testing
- Pravastatin 40 Mg Oral Tablet
- Where
- Australia
- Volunteers
- 48 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Nasopharyngeal Carcinoma (NPC), Recurrent Nasopharyngeal Neoplasms
Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
This single-arm, single-center phase II trial evaluates the safety and efficacy of a non-continuous radio-immunotherapy strategy for recurrent nasopharyngeal carcinoma (NPC) unsuitable for surgery.
- Trial name
- REDEFINE (NCT07277764)
- Testing
- High-Low Dose Radiotherapy
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.